Skip to main content

Bristol-Myers Squibb Co's shares rose more than 7 per cent Monday after news over the weekend that its experimental drug ipilimumab extended survival in patients with deadly skin cancer.

Bristol's ipilimumab added an average of four months to the lives of patients with advanced melanoma, according to data released at a major cancer meeting, marking a huge advance in a disease littered with failures.

Celgene Corp. shares also rose more than 4 per cent after data from the meeting on its multiple myeloma drug Revlimid showed that when taken as maintenance therapy following stem-cell transplantation, it reduced the risk of disease progression more than 50 per cent.

Story continues below advertisement

Sanford Bernstein analyst Geoff Porges said the eagerly anticipated presentations at the meeting on Revlimid "did not disappoint ... showing a conclusive improvement" and Jefferies analysts upgraded Celgene shares to "buy" from "hold."

However, shares of smaller biotechnology companies Delcath Systems Inc. , ArQule Inc. and Celldex Therapeutics each slumped more than 10 per cent after data on their respective products were released at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

Delcath's drug delivery system helped melanoma patients whose cancer had spread to their liver, live more than three times as long as patients treated with best available care. But one researcher said the system causes "a fair amount of toxicity" and would need to be used only at centers with expertise in monitoring patients.

ArQule's experimental drug ARQ197 showed that it was most effective in certain types of lung cancer tumors, but investors apparently were not impressed.

The success of Bristol's ipilimumab heralded a new era of cancer "immunotherapy" - drugs that enlist the help of the immune system to fight the disease, researchers said on Saturday.

Credit Suisse analyst Catherine Arnold raised her forecast for the drug's sales to $720 million (U.S.)in 2015, from $500 million on the strength of the data.

"While some regulatory risk still exists ... at minimum the probability of success for the drug reaching the market has now increased," Ms. Arnold said in a research note.

Story continues below advertisement

Goldman Sachs analyst Jami Rubin raised Bristol to "buy" from "neutral," calling ipilimumab "the first pipeline drug in the pharma sector that has the potential to re-rate the way investors perceive pharma terminal growth rates."

Industry analysts at Jefferies said the success underscored the drug's $1 billion-plus sales potential, although questions remain about adverse events. There is also a potential competitor on the horizon in the form of Roche's experimental treatment PLX4032.

Pfizer's shares also rose 0.3 per cent, in line with the rise for U.S. and European drug stocks, after the world's largest drugmaker's experimental medicine crizotinib showed it shrank lung cancer tumors in more than half of treated patients.

Leerink Swann analysts called the results impressive but said the initial opportunity for the treatment was modest because a relatively small number of patients are estimated to have the genetic mutation targeted by the drug.

Novartis AG shares gained 0.6 per cent following weekend news about two rivals to its leukemia drug Gleevec - a competitor called from Sprycel from Bristol-Myers and Novartis's own follow-on product Tasigna.

Data at ASCO showed patients on both the new drugs did better than those on Gleevec.

Story continues below advertisement

Analysts at Morgan Stanley said Tasigna appeared to have the edge, with superior safety and efficacy compared with Sprycel.

Roche Holding AG - which along with Novartis had the most data being shown at the world's top cancer meeting - reported results of a high-profile clinical study showing the benefits of its blockbuster drug Avastin in ovarian cancer.

However, the impact was limited since the company had previously announced the ovarian study had been positive and some investors were also concerned about questions by an outside expert at ASCO about the design of the study and its findings. Roche stock slid 0.6 per cent.

Among biotech stocks, British minnow Antisoma, whose stock plunged 70 per cent in March when a lung cancer drug it was developing with Novartis failed in a Phase III trial, saw a partial revival in its fortunes on hopes for other drugs in earlier-stage development.

Shares in Antisoma, which presented updates on both AS1413 and AS1411 at ASCO, rose 19 per cent.

Report an error

The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

We’ve made some technical updates to our commenting software. If you are experiencing any issues posting comments, simply log out and log back in.

Discussion loading… ✨